{
  "symbol": "ARTV",
  "company": "Artiva Biotherapeutics, Inc.",
  "generated_at": "2026-06-24T07:36:44.971Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-05-20T03:25:43.594Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Triggered anti-signal gates for >10% dilution (48% follow-on) and low liquidity. Additionally, lacks tradable options infrastructure and traditional valuation metrics, making a publishable structure impossible.",
      "trigger": "[insider_cluster_universe] 5 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-20T03:25:43.563Z",
      "skip": true,
      "reason": "Triggered anti-signal gates for >10% dilution (48% follow-on) and low liquidity. Additionally, lacks tradable options infrastructure and traditional valuation metrics, making a publishable structure impossible.",
      "score": 10,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 5,
        "mispricing": 0,
        "quality": 0,
        "technical": 5
      },
      "debug_path": "drafts/2026-05-20-ARTV.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-20T03:24:26.904Z",
      "summary": "Artiva is a pre-revenue clinical-stage biotech with AlloNK (NK cell therapy) showing 71% ACR50 response in refractory RA patients — a strong Phase 2a signal that prompted FDA alignment on a Phase 3 registrational trial. The May 2026 follow-on offering raised $300M at $11.52, diluting shares by ~48%, which likely explains the recent stock pullback from ~$13 to $8.55. RA Capital — a 10% owner and board member — was the lead investor in that offering, buying ~6.5M new shares (P code), demonstrating conviction at current levels. The five Form 4 filings triggering this investigation are uniformly sell-to-cover transactions from RSU vest dates — not discretionary open-market sales. Diego Miralles's receipt of RSUs and options as a $600K/yr inducement hire is the only true equity-incentive signal in the cluster.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 23,
      "walltime_min": 35,
      "debug_path": "dossiers/2026-05-20-ARTV.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "ARTV",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (396.3%)",
      "rsi_neutral": "0 (59.2)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (7d ago)",
      "from_high": "0 (-26.8%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 396.3% · RSI 59.2 · above_both · -26.8% from high",
    "last_close": 9.8,
    "one_month_ago_close": 7.99,
    "twelve_month_ago_close": 1.61,
    "twelve_one_momentum_pct": 396.27,
    "rsi_14": 59.2,
    "ma_stack": "above_both",
    "from_period_high_pct": -26.81,
    "period_high": 13.39,
    "price_targets": {
      "bear": 5.55,
      "fair": 18.34,
      "bull": 41,
      "bear_return_pct": -43.4,
      "fair_return_pct": 87.1,
      "bull_return_pct": 318.4,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 23,
        "target_mean": 35.8,
        "target_high": 41,
        "analyst_count": 5
      }
    },
    "generated_at": "2026-06-24T07:36:44.967Z"
  }
}